


APPLICANT(S): ZIV, Ilan Et al.
SERIAL NO.: 10/799,586
FILED: March 15, 2004
Page 2

AMENDMENTS TO THE CLAIMS

Please add or amend the claims to read as follows, and cancel without prejudice or disclaimer to resubmission in a divisional or continuation application claims indicated as cancelled:

1 – 6 (Canceled)


7. (Currently amended) A compound represented by the structure as set forth in formula (II):



including pharmaceutically acceptable salts hydrates, solvates and metal chelates of the compound represented by the structure as set forth in formula (II) and solvates and hydrates of said salts; wherein R¹ is hydrogen or C₁, C₂, C₃, C₄, C₅ or C₆ linear or branched alkyl alkyl, and R² is a C₁, C₂, C₃, C₄, C₅ or C₆ fluoro-alkyl.

APPLICANT(S): ZIV, Ilan Et al.
SERIAL NO.: 10/799,586
FILED: March 15, 2004
Page 3


8. (Original) A compound represented by the structure as set forth in formula (III):



III

including pharmaceutically acceptable salts hydrates, solvates and metal chelates of the compound represented by the structure as set forth in formula (II) and solvates and hydrates of said salts; wherein R³ is hydroxyl or F and k is an integer selected from 1, 2, 3, 4 and 5.

9. (Original) A compound represented by the structure as set forth in formula (IV):




IV

including pharmaceutically acceptable salts hydrates, solvates and metal chelates of the compound represented by the structure as set forth in formula (IV) and solvates and hydrates of said salts; wherein m stands for an integer of 0, 1, 2, 3 or 4; and D is selected from hydrogen; a drug to be targeted to a cell undergoing perturbation of the

APPLICANT(S): ZIV, Ilan Et al.
SERIAL NO.: 10/799,586
FILED: March 15, 2004
Page 4

normal organization of its plasma membrane (PNOM-cell); and a marker for diagnostics selected from a marker for imaging and a metal chelate; said marker for imaging being selected from the group comprising a fluorescent label, a radio-label, a marker for X-ray, a marker for MRI, a marker for PET scan and a label capable of undergoing an enzymatic reaction that produces a detectable color.

10. (Currently amended) A compound ~~according to claim 7~~ represented by the structure as set forth in formula (V):




V

including pharmaceutically acceptable salts hydrates, solvates and metal chelates of the compound represented by the structure as set forth in formula (V) and solvates and hydrates of said salts; wherein J is selected from F and -OH.

11. (Canceled)

12. (Original) A compound represented by the structure set forth in formula VII:


APPLICANT(S): ZIV, Ilan Et al.
 SERIAL NO.: 10/799,586
 FILED: March 15, 2004
 Page 5



VII

including pharmaceutically acceptable salts hydrates, solvates and metal chelates of the compound represented by the structure as set forth in formula (VII) and solvates and hydrates of said salts, wherein Q is selected from Technetium, oxo-Technetium, Rhenium and oxo-Rhenium, R^4 is selected from hydrogen, C_1 , C_2 , C_3 , C_4 , C_5 , and C_6 linear or branched alkyl, and p stands for an integer, selected from 1, 2, 3, 4 and 5.

13. (Original) A compound according to claim 12 represented by the structure set forth in formula VIII:




VIII

including pharmaceutically acceptable salts hydrates, solvates and metal chelates of the compound represented by the structure as set forth in formula (VIII) and solvates and hydrates of said salts, wherein Q is selected from Technetium, oxo-Technetium, Rhenium and oxo-Rhenium.

14. (Original) A compound represented by the structure set forth in formula IX:


APPLICANT(S): ZIV, Ilan Et al.
 SERIAL NO.: 10/799,586
 FILED: March 15, 2004
 Page 6



IX

including pharmaceutically acceptable salts hydrates, solvates and metal chelates of the compound represented by the structure as set forth in formula (IX) and solvates and hydrates of said salts, wherein Q is selected from Technetium, oxo-Technetium, Rhenium and oxo-Rhenium, R^4 is selected from hydrogen, C_1 , C_2 , C_3 , C_4 , C_5 , and C_6 linear or branched alkyl, and p stands for an integer, selected from 1, 2, 3, 4 and 5.

15. (Currently amended) A compound represented by the structure as set forth in formula (X):




X

including pharmaceutically acceptable salts hydrates, solvates and metal chelates of the compound represented by the structure as set forth in formula (X) and solvates and hydrates of said salts; wherein R^5 is selected from hydrogen, C_1 , C_2 , C_3 , C_4 , C_5 , and C_6 linear or branched alkyl, C_1 , C_2 , C_3 , C_4 , C_5 , and C_6 linear or branched fluoro-alkyl, and C_1 , C_2 , C_3 , C_4 , C_5 , and C_6 linear or branched hydroxy-alkyl; and q stands for an integer, selected from 1, 2, 3, 4 and 5, wherein Y is selected from a NH dansyl and fluorescein.

APPLICANT(S): ZIV, Ilan Et al.
SERIAL NO.: 10/799,586
FILED: March 15, 2004
Page 7


16. (Currently amended) A compound according to claim 15 represented by the structure as set forth in formula (XI):



XI

including pharmaceutically acceptable salts hydrates, solvates and metal chelates of the compound represented by the structure as set forth in formula (XI) and solvates and hydrates of said salts; wherein J is selected from hydrogen, methyl, -F and -OH.

17. (Currently amended) A compound according to claim 15 represented by the structure as set forth in formula (XII):




XII

including pharmaceutically acceptable salts hydrates, solvates and metal chelates of the compound represented by the structure as set forth in formula (XII) and solvates and hydrates of said salts; wherein J is selected from hydrogen, methyl, -F and -OH.

APPLICANT(S): ZIV, Ilan Et al.
SERIAL NO.: 10/799,586
FILED: March 15, 2004
Page 8

18. (Original) A compound represented by the structure as set forth in formula (XIII):



XIII

including pharmaceutically acceptable salts hydrates, solvates and metal chelates of the compound represented by the structure as set forth in formula (XIII) and solvates and hydrates of said salts; wherein Z^1 and Z^2 are each selected from hydrogen and C_1 , C_2 , C_3 , C_4 , C_5 alkyl, hydroxy-alkyl or fluoro-alkyl; Z groups may be the same or different.

19. (Currently amended) A compound according to the structure set forth in ~~formulae I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII or XIII~~ any one of claims 7-10 and 12-18, comprising or being linked to a marker for imaging, wherein said marker for imaging is Tc, Tc=O, In, Cu, Ga, Xe, Tl, Re and Re=O, ^{123}I , ^{131}I , Gd(III), Fe(III), Fe_2O_3 , Fe_3O_4 , Mn(II) ^{18}F , ^{15}O , ^{18}O , ^{11}C , ^{13}C , ^{124}I , ^{13}N , ^{75}Br , Tc-99m or In-111.

20 - 23 (Canceled)